A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

Conditions

• Pulmonary Arterial Hypertension

Interventions

• DRUG: Sotatercept
• OTHER: Placebo

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA